Phcog.Net logo

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Article

    Pharmacological Evaluation of Green Chilli in Alzheimer’s Disease

    Pandurangan Perumal1, Desmond Yong Hua Chong2 Corresponding author

    1. 1Department of Pharmaceutical Analysis, Sree Vidyanikethan College of Pharmacy, Tirupathi, Andhra Pradesh, INDIA.
    2. 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Asian Institute of Medicine Science Technology (AIMST) University, Bedong, Kedah Darul Aman, MALAYSIA.

    CORRESPONDENCE

    Pandurangan Perumal

    Department of Pharmaceutical Analysis, Sree Vidyanikethan College of Pharmacy, Tirupathi, Andhra Pradesh, INDIA.

    perupharma78@gmail.com

    Received: 22-10-2021; Revised: 04-11-2021; Accepted: 02-12-2021.

    Volume 14, Issue 1 · pp. 61–70 · PUBLISHED · DOI: 10.5530/pres.14.1.10

    View on Pharmacogn. Res. original site ↗

    ABSTRACT

    Background:Green chilli pepper (Capsicum annum L. car frutescens) is popular as a spice used in many cuisines across the world. Capsaicin, as the pharmacologically active composition of chilli pepper, has been shown to possess antioxidant, local analgesic, and hypoglycemic effects according to many studies conducted on the red chilli pepper. However, there is no data associated with the role of green chilli peppers in Alzheimer’s disease (AD) caused by capsaicin, rather than red chilli peppers. Objectives: To evaluate the acetylcholinesterase (AChE) and beta-secretase enzyme inhibition of ethanolic extract of Capsicum frutescens (EECF) or known as green chilli in in-vitromanner. Materials and Methods: Extraction was carried out on the fruits ofCapsicum frutescens with ethanol. Its ethanolic extract in different concentrations was applied as the analyte to test its anti-acetylcholinesterase activity and enzymatic inhibitory action on the beta-secretase. Donepezil with various concentrations was also prepared as the control set for comparison of effect with EECF. Both the analytes were tested using the QuantiChromTM and BACE-1 FRET assay kits, for evaluation of inhibition activity against acetylcholinesterase and BACE-1 respectively.Results: There is significant increase in the percentage of inhibition against acetylcholinesterase and BACE-1 when tested with increased concentration of EECF. Compared to inhibitory effects by EECF, donepezil exhibited higher values of IC50 against both the assayed key enzymes, though also demonstrated vital inhibitory actions in both assays. EECF also showed higher potency in controlling AD progression in terms of inhibition against acetylcholinesterase, shown by IC50 value for the acetylcholinesterase, if compared to IC50 value for BACE-1.Conclusion: Green chilli or EECF has potential to have inhibitory action on acetylcholinesterase and beta-secretase enzymes in patients with AD, but limited to optimum concentration or dose.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Perumal, P., & Chong, D. Y. H. (). Pharmacological Evaluation of Green Chilli in Alzheimer’s Disease. Pharmacognosy Research, 14(1), 61–70. https://doi.org/10.5530/pres.14.1.10